Your Article Summary
See Latest ArticlesProbiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada
Current Medical Research and Opinion, 07/01/09
Ranganathan N et al. - Orally administered probiotic bacteria selected to metabolize nitrogenous wastes may be tolerated for as long as 6 months. A major limitation of this trial is its small size that may have precluded detection of changes in other biochemical or hematologic parameters that would be evident in larger cohorts. Extension of the evaluation of this probiotic bacterial mixture will include a dose escalation trial in a similar prospective, placebo-controlled, and double-blind study site.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09